Publications

Select a Category


Radiopharmaceutical Therapy


Personalized Dosimetry for MRT: Why does it matter?

Eberlein U, Cremonesi M, and Lassmann M. Individualized dosimetry fortheranostics: Necessary, nice to have, or counterproductive? J Nucl Med2017; 58(Suppl 2): 97S-103S.


Stabin MG, Madsen MT, and Zaidi H. Personalized dosimetry is a must for appropriate molecular radiotherapy. Med Phys 2019; 46(11): 4713–4716.


Strigari L, Konijnenberg M, Chiesa C, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014; 41(10):1976-1988.



Personalized Dosimetry for MRT: How to achieve it?

Nelson AS, Mirando D, Kruzer A, and Niman R. Dosimetry for Targeted Molecular Radiotherapy (White Paper).



Dewaraja YK, Ljungberg M, Green AJ, et al. MIRD pamphlet No. 24:Guidelines for quantitative 131I SPECT in dosimetry applications. J Nucl Med2013; 54(12): 2182-2188.


Sarrut D, Halty A, Badel J, et al. Voxel-based multimodal fitting method for modeling time activity curves in SPECT images. Med Phys 2017; 44(12):6280-6288.




Quantitative SPECT Reconstruction

Nelson AS and Horstman BP. Quantitative SPECT / CT Reconstruction with SPECTRA TM Quant (White Paper).


Ritt P, Vija H, Hornegger J, et al. Absolute quantification in SPECT. Eur J NuclMed Mol Imaging 2011; 38(Suppl 1): 69–77.



Peters SMB., Meyer Viol SL, van der Werf NR, et al. Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT/CT systems. EJNMMI Phys 2020; 7(1): 9 (2020).



Dosimetry for Patient Outcome Prediction and Treatment Planning: Lu-177

Del Prete M, Buteau F, Arsenault F, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging 2019; 46: 728‑742.


Mirando D, Dewajara YK, Kruzer A, and Nelson A. Personalized therapy planning for 177Lu-DOTATATE using a kidney-driven dose optimization method. J Nucl Med 2019; 60(Suppl 1): 270.



Sundlöv A, Sjögreen-Gleisner K, Svensson J, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging 2017; 44(9): 1480–1489.





Dosimetry for Patient Outcome Prediction and Treatment Planning: I-131

Flux GD, Haq M, Chittenden SJ, et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37: 270–275.




Hybrid SPECT/Planar Dosimetry

Cole NM, Mirando D, Nelson AS, et al. Hybrid SPECT/Planar Dosimetry for Targeted Molecular Radiotherapy (White Paper).



Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, Robertson JS, Howell RW, Wessels BW, Fisher DR, Weber DA, Brill AB. MIRD Pamphlet 16: Techniques for Quantitative Radiopharmaceutical Biodistribution Data Acquisition and Analysis for Use in Human Radiation Dose Estimates. J Nucl Med 1999; 40:37S-61S.



Single Timepoint Dosimetry

Hänscheid H, Lapa C, Buck AK, et al. Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days. Nucl Med. 2018; 59(1):75-81.


Garske U, Sandström M, Johansson S, et al. Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. Acta Oncol. 2012; 51(1):86-96.



Del Prete M, Arsenault F, Saighi N, et al. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT. EJNMMI Phys. 2018; 5(1):25.




You may also be interested in: